Advances in antibody-based therapy in oncology

被引：65

作者：

Zinn, Sacha ^{[1
,2
]}

Vazquez-Lombardi, Rodrigo ^{[1
,2
,7
]}

Zimmermann, Carsten ^{[3
,4
]}

Sapra, Puja ^{[5
]}

Jermutus, Lutz ^{[6
]}

Christ, Daniel ^{[1
,2
]}

机构：

[1] Garvan Inst Med Res, Sydney, NSW, Australia

[2] Univ New South Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia

[3] Univ San Diego, Knauss Sch Business, San Diego, CA USA

[4] Univ Calif San Diego, La Jolla, CA USA

[5] AstraZeneca, Oncol R&D, Biol Engn & Targeted Delivery, Gaithersburg, MD USA

[6] Res & Early Dev, AstraZeneca, BioPharmaceut R&D, Cambridge, England

[7] Engimmune Therapeut, Allschwil, Switzerland

来源：

NATURE CANCER | 2023年 / 4卷 / 02期

基金：

英国医学研究理事会;

关键词：

C-RECEPTOR POLYMORPHISMS; I-RELATED RECEPTOR; T-CELL EXHAUSTION; SERUM HALF-LIFE; FC-GAMMA-RIIB; MONOCLONAL-ANTIBODY; DEPENDENT MECHANISMS; ANTITUMOR IMMUNITY; AGONISTIC ANTIBODY; EFFECTOR FUNCTIONS;

D O I：

10.1038/s43018-023-00516-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this review article, Christ and colleagues discuss the recent developments in antibody-based cancer therapies. Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discuss molecular structure and mechanisms of action and provide updates on clinical development and practice.

引用

页码：165 / 180

页数：16

共 50 条

[41] FLT3 antibody-based therapy for leukemia
Li, Yiwen
[J]. DRUG DEVELOPMENT RESEARCH, 2006, 67 (06) : 495 - 500
[42] Novel antibody-based therapy for acute lymphoblastic leukaemia
Goekbuget, Nicola
Hoelzer, Dieter
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 701 - 713
[43] Eph receptors as cancer targets for antibody-based therapy
Tang, Fenny H. F.
Davis, Deodate
Arap, Wadih
Pasqualini, Renata
Staquicini, Fernanda I.
[J]. RECEPTOR TYROSINE KINASES, 2020, 147 : 303 - 317
[44] Antibody-based therapy to combat Staphylococcus aureus infections
Francois, B.
Barraud, O.
Jafri, H. S.
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (04) : 219 - 221
[45] Anti-CD30 antibody-based therapy
Koon, HB
Junghans, RP
[J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 588 - 593
[46] Monoclonal antibody-based therapy for renal cell carcinoma
Oosterwijk, E
Divgi, CR
Brouwers, A
Boerman, OC
Larson, SM
Mulders, P
Old, LJ
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (03) : 623 - +
[47] Role of FcγRs in Antibody-Based Cancer Therapy
Graziano, Robert F.
Engelhardt, John J.
[J]. FC MEDIATED ACTIVITY OF ANTIBODIES: STRUCTURAL AND FUNCTIONAL DIVERSITY, 2019, 423 : 13 - 34
[48] Recent advances in antibody-based immunotherapy strategies for COVID-19
Esmaeilzadeh, Abdolreza
Rostami, Samaneh
Yeganeh, Pegah M.
Tahmasebi, Safa
Ahmadi, Majid
[J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (10) : 1389 - 1412
[49] Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis
Kharga, Kusum
Kumar, Lokender
Patel, Sanjay Kumar Singh
[J]. BIOMEDICINES, 2023, 11 (03)
[50] Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas
Huang, Xin
Shi, Shuyou
Wang, Hongrui
Zhao, Tiesuo
Wang, Yibo
Huang, Sihua
Su, Yingying
Zhao, Chunyan
Yang, Ming
[J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 117

← 1 2 3 4 5 →